ClinicalTrials.gg

Program

andexanet alfa

Also written as “Andexanet”, “Andexanet alfa” and “Andexanet alfa (infusion IV)”.

Its studies are mostly in Hemorrhage · Thrombosis, led by AstraZeneca.

Furthest: phase 4, since Aug 30, 201814 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca140 open or runningphase 4since Aug 30, 2018Dec 18, 2012none ahead

Also a collaborator on its studies: parexel and portola-pharmaceuticals-llc-a-wholly-owned-subsidiary-of-ale.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 18, 2012First study: phase 2 study in Healthy VolunteersFirst studyNCT01758432 · 54 enrolled · United States
  2. Dec 27, 2012Phase 1 study in HealthyNCT03218241 · 32 enrolled · United States
  3. Apr 28, 2014Phase 3 study in HemorrhageNCT02207725 · 68 enrolled · United States
  4. Aug 18, 2014Phase 3 study in HemorrhageNCT02220725 · 80 enrolled · United States
  5. Dec 18, 2014Phase 3 study in HemorrhageNCT02329327 · 479 enrolled · United States, Belgium, Canada and more
  6. Mar 7, 2017Phase 1 study in HemorrhageNCT03083704 · 153 enrolled · United States
  7. Sep 27, 2017Phase 2 study in HemorrhageNCT03330457 · 18 enrolled · United States
  8. May 15, 20183 phase 2 studies in Healthy VolunteersNCT03578146, NCT03551743, NCT03551730
  9. Aug 30, 2018Phase 4 study in ThrombosisNCT03661528 · 530 enrolled · United States, Austria, Belgium and more
  10. Jan 14, 2020Phase 2 study in ThrombosisNCT04233073 · 10 enrolled · United States, Austria, France and more
  11. Jun 9, 2023Phase 3 study in Urgent SurgeryNCT05926349
  12. Nov 27, 2025Phase 1 study in Healthy ParticipantsNCT07312851 · 191 enrolled · Germany, United Kingdom

TargetBeta

TFPI →read by rule
“Rivaroxaban sequestering agent; Apixaban sequestering agent; Tissue factor pathway inhibitor inhibitor”ChEMBL 37, by rule

Other programs on TFPI

ProgramCompanyFurthest phaseStudies
marstacimabrulePfizerphase 310

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07312851Healthy Participants · Germany, United Kingdom1CompletedJun 22, 2026191
NCT05926349Urgent Surgery3WithdrawnJan 5, 20270
NCT04233073Thrombosis · United States, Austria, France and more2TerminatedNov 23, 202110
NCT03661528Thrombosis · United States, Austria, Belgium and more4CompletedMay 27, 2023530
NCT03578146Healthy Volunteers2CompletedSep 201548
NCT03551743Healthy Volunteers2CompletedSep 201528
NCT03551730Healthy Volunteers · United States2CompletedSep 201527
NCT03330457Hemorrhage · United States2TerminatedFeb 22, 201618
NCT03083704Hemorrhage · United States1CompletedSep 28, 2017153
NCT02329327Hemorrhage · United States, Belgium, Canada and more3CompletedSep 24, 2020479
NCT02220725Hemorrhage · United States3CompletedAug 201580
NCT02207725Hemorrhage · United States3CompletedApr 201568
NCT03218241Healthy · United States1CompletedSep 201232
NCT01758432Healthy Volunteers · United States2CompletedSep 201554

How it is read

Names in the registry

  • “Andexanet”, 3 entries
  • “Andexanet alfa”, 2 entries
  • “andexanet alfa”, 2 entries
  • “Andexanet alfa (infusion IV)”, 1 entry
  • “Andexanet alfa (Gen 1 Process 2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.